BioMedNewsBreaks – Revive Therapeutics Ltd. (CSE: RV) (OTC: RVVTF) Receives IRB Approval for Bucilliamine COVID-19 Treatment Program

Revive Therapeutics (CSE: RVV) (OTC: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced that is has received approval from the independent Institutional Review Board (“IRB”) for one of its programs. The program is Revive’s expanded access protocol (“EAP”) for compassionate use of Bucillamine in the treatment of COVID-19. The EAP comprises a multi-center, open-label study of Bucillamine in hospitalized patients suffering from severe COVID-19. The study calls for patients to receive Bucillamine 200 mg orally, three times a day for up to 14 days. Patients will be monitored to evaluate the safety and efficacy of Bucillamine at that dosage. Follow-up safety assessments will also be performed. “With the IRB approval of the expanded access protocol by Advarra, a premier IRB services company in North America, hospitalized patients with severe COVID-19 may access Bucillamine under the FDA compassionate use program under medical supervision by their physician,” Revive CEO Michael Frank stated in the press release. “The EAP serves as an option for patients that are not eligible for inclusion criteria in our Phase 3 clinical study in COVID-19, and the resulting data from the EAP will be valuable in supporting our clinical development of Bucillamine.”

To view the full press release, visit http://ibn.fm/dkFIX

About Revive Therapeutics Ltd.

Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug-development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations. Currently, Revive is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. With its recent acquisition of Psilocin Pharma Corp., Revive is advancing the development of psilocybin-based therapeutics in various diseases and disorders. Revive’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases, and the company was granted FDA orphan drug status designation for the use of cannabidiol (“CBD”) to treat autoimmune hepatitis (liver disease) and reperfusion injury from organ transplantation. For more information about the company, visit www.ReviveThera.com.

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

More News From The World Agenda

Stocks rise as China confirms trade deal signing next week

Sep 28, 2020

NEW YORK — U.S stocks climbed in morning trading on Thursday as investors cheered confirmation from China that its top trade official will head to Washington next week to sign a preliminary trade deal. The “Phase 1” accord is the opening step on a possible path toward a broader agreement between the nations. President Donald Trump has said he will travel to Beijing after the initial signing to start the second stage of talks. Every major index is on track for a record as Wall Street distances itself from a bout of anxiety over the last week because of tensions...

Counting whales from space pitched as key to saving them

Sep 28, 2020

PORTLAND, Maine — An aquarium and an engineering firm in Massachusetts are partnering on a project to better protect whales by monitoring them from space. New England Aquarium of Boston and Draper of Cambridge say whale conservation needs new, higher-tech solutions to protect whales from extinction. So, the pair is working together using data from sources such as satellites, sonar and radar to keep a closer eye on how many whales are in the ocean. The effort has an easy to understand name for a project involving complex data and surveillance — the aquarium and firm are calling the project...

US heads to court to build Trump border wall in Texas

Sep 28, 2020

HOUSTON — Three years into Donald Trump's presidency, the U.S. government is ramping up its efforts to seize private land in Texas to build a border wall. Trump's signature campaign promise has consistently faced political, legal, and environmental obstacles in Texas, which has the largest section of the U.S.-Mexico border, most of it without fencing. And much of the land along the Rio Grande, the river that forms the border in Texas, is privately held and environmentally sensitive. Almost no land has been taken so far. But Department of Justice lawyers have filed three lawsuits this month seeking to take...

Space Force will start small but let Trump claim a big win

Sep 28, 2020

WASHINGTON — The Trump administration is celebrating the launch of Space Force, the first new military service in more than 70 years. In signing the 2020 National Defense Authorization Act that includes Space Force, Trump on Friday can claim a victory for one of his top national security priorities just two days after being impeached by the House. It is part of a $1.4 trillion government spending package — including the Pentagon's budget — that provides a steady stream of financing for Trump's U.S.-Mexico border fence and reverses unpopular and unworkable automatic spending cuts to defense and domestic programs. Space...

House passes $1.4T government spending bill amid impeachment

Sep 28, 2020

WASHINGTON — The Democratic-controlled House voted Tuesday to pass a $1.4 trillion government spending package, handing President Donald Trump a victory on his U.S.-Mexico border fence while giving Democrats spending increases across a swath of domestic programs. The hard-fought legislation also funds a record Pentagon budget and is serving as a must-pass legislative locomotive to tow an unusually large haul of unrelated provisions into law, including an expensive repeal of Obama-era taxes on high-cost health plans, help for retired coal miners, and an increase from 18 to 21 in the nationwide legal age to buy tobacco products. The two-bill package,...

Here at The World Agenda, we bring innovation to digital news for you to keep abreast of worldwide news instantly anywhere.

Contact us: sales[at]theworldagenda.com